Why the study?
Does intravenous MSC application reduce cardiac inflammation and modulate monocyte trafficking in mice with CVB3-induced myocarditis?
Population
C57BL/6 mice with Coxsackievirus B3 (CVB3)-induced myocarditis
Comparison
Intravenous injection of 1 x 10^6 Mesenchymal… vs CVB3 infected mice without MSC treatment
Design
Preclinical
Follow-up
6 days post-injection
Authors
Loading...
Should not yet change myocarditis practice; hypothesis-generating for MSC monocyte modulation in viral models.
Does intravenous MSC application reduce cardiac inflammation and modulate monocyte trafficking in mice with CVB3-induced myocarditis?
Mesenchymal stromal cell application in CVB3-induced myocarditis modulates monocyte trafficking, reducing pro-inflammatory monocytes and increasing anti-inflammatory monocytes, offering a potential strategy for resolving cardiac inflammation.
Miteva et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: